Imugene Dirección

Dirección controles de criterios 1/4

Imugene's El consejero delegado es Leslie Chong , nombrado en Nov 2016, tiene un mandato de 7.25 años. la remuneración anual total es A$2.48M , compuesta por 30.2% salario y 69.8% primas, incluidas acciones y opciones de la empresa. posee directamente 1.09% de las acciones de la empresa, por valor de A$8.79M . La antigüedad media del equipo directivo y del consejo de administración es de 1 años y 5.4 años respectivamente.

Información clave

Leslie Chong

Chief Executive Officer (CEO)

AU$2.5m

Compensación total

Porcentaje del salario del CEO	30.2%
Permanencia del CEO	7.4yrs
Participación del CEO	1.1%
Permanencia media de la dirección	1.1yrs
Promedio de permanencia en la Junta Directiva	5.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Leslie Chong en comparación con los beneficios de Imugene?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-AU$89m
Sep 30 2023	n/a	n/a	-AU$64m
Jun 30 2023	AU$2m	AU$750k	-AU$38m
Mar 31 2023	n/a	n/a	-AU$39m
Dec 31 2022	n/a	n/a	-AU$40m
Sep 30 2022	n/a	n/a	-AU$39m
Jun 30 2022	AU$1m	AU$600k	-AU$38m
Mar 31 2022	n/a	n/a	-AU$33m
Dec 31 2021	n/a	n/a	-AU$27m
Sep 30 2021	n/a	n/a	-AU$23m
Jun 30 2021	AU$789k	AU$408k	-AU$18m
Mar 31 2021	n/a	n/a	-AU$15m
Dec 31 2020	n/a	n/a	-AU$12m
Sep 30 2020	n/a	n/a	-AU$11m
Jun 30 2020	AU$733k	AU$375k	-AU$11m
Mar 31 2020	n/a	n/a	-AU$10m
Dec 31 2019	n/a	n/a	-AU$9m
Sep 30 2019	n/a	n/a	-AU$8m
Jun 30 2019	AU$777k	AU$350k	-AU$8m
Mar 31 2019	n/a	n/a	-AU$7m
Dec 31 2018	n/a	n/a	-AU$6m
Sep 30 2018	n/a	n/a	-AU$5m
Jun 30 2018	AU$403k	AU$300k	-AU$4m
Mar 31 2018	n/a	n/a	-AU$3m
Dec 31 2017	n/a	n/a	-AU$3m
Sep 30 2017	n/a	n/a	-AU$3m
Jun 30 2017	AU$337k	AU$290k	-AU$3m

Compensación vs. Mercado: Leslie($USD1.63M) está por encima de la media de empresas de tamaño similar en el mercado Australian ($USD795.85K).

Compensación vs. Ingresos: Leslieha aumentado mientras la empresa no es rentable.

CEO

Leslie Chong

7.4yrs

Permanencia

AU$2,482,687

Compensación

Ms. Leslie Chong served as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020 until July 2023. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Hopper	Executive Chairman	11.5yrs	AU$515.23k	5.77% A$ 40.1m
Leslie Chong	CEO, MD & Executive Director	7.4yrs	AU$2.48m	1.09% A$ 7.6m
Michael Tonroe	CFO & Company Secretary	1.6yrs	AU$839.00k	sin datos
Nicholas Ede	Head of Corporate Development	less than a year	AU$874.91k	0.24% A$ 1.7m
Monil Shah	Chief Business Officer	2.8yrs	AU$799.20k	sin datos
Bradley Glover	Chief Operating Officer	less than a year	sin datos	sin datos
Ursula McCurry	Senior Vice President of Clinical Operations	2.3yrs	sin datos	sin datos
John Byon	Senior Vice President of Clinical Development	less than a year	sin datos	sin datos
Joseph Woodard	Chief Medical Officer	less than a year	sin datos	sin datos

1.1yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: IMUEl equipo directivo de la empresa no se considera experimentado ( 1 años de permanencia media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Hopper	Executive Chairman	11.5yrs	AU$515.23k	5.77% A$ 40.1m
Leslie Chong	CEO, MD & Executive Director	6.1yrs	AU$2.48m	1.09% A$ 7.6m
Jens Eckstein	Independent Non-Executive Director	4.9yrs	AU$115.52k	0.28% A$ 2.0m
Kimberlee Drapkin	Non-Executive Director	less than a year	AU$2.08k	0.0016% A$ 11.3k
Yuman Fong	Chair of Oncolytic Virotherapy Scientific Advisory Board	4.4yrs	sin datos	sin datos
Ursula Wiedermann	Member of Scientific Advisory Board	no data	sin datos	sin datos
Neil Segal	Member of Scientific Advisory Board	10yrs	sin datos	sin datos
Josep Tabernero	Member of Scientific Advisory Board	5.5yrs	sin datos	sin datos
Yelena Janjigian	Scientific Advisory Board Member	8yrs	sin datos	sin datos
Peter Schmid	Member of Scientific Advisory Board	6.3yrs	sin datos	sin datos
Tanios Bekaii-Saab	Member of Scientific Advisory Board	5.6yrs	sin datos	sin datos
Pravin T. Kaumaya	Member of Scientific Advisory Board	5.5yrs	sin datos	sin datos

5.6yrs

Permanencia media

Junta con experiencia: La junta directiva de IMU se considera experimentada (5.4 años de antigüedad promedio).

Imugene Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Imugene Limited, Annual General Meeting, Nov 30, 2023

Less than half of directors are independent

Imugene Limited Appoints Paul Woodard as Chief Medical Officer

Imugene Limited Appoints John Byon as Senior Vice President of Clinical Development

Imugene Limited Appoints Dr Bradley Glover as Chief Operating Officer

Imugene Appoints Dr Weitzman Interim Chief Medical Officer

Recent updates

Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment

Imugene Limited, Annual General Meeting, Nov 30, 2023

No longer forecast to breakeven

New minor risk - Share price stability

Less than half of directors are independent

Imugene Limited Appoints Paul Woodard as Chief Medical Officer

Imugene Limited Appoints John Byon as Senior Vice President of Clinical Development

Imugene Limited Appoints Dr Bradley Glover as Chief Operating Officer

Imugene Appoints Dr Weitzman Interim Chief Medical Officer

Forecast to breakeven in 2026

Imugene Limited Announces Board Changes

Imugene Limited Announces VAXINIA Trial Advances to Combination Cohort 1 & Monotherapy Cohort 3

Imugene Limited Receives Vaxinia Ethics Approval in Australia

Imugene Limited Presents New and First CHECKvacc Data At the 2022 San Antonio Breast Cancer Symposium

Imugene Limited Announces First Patient Dosed in VAXINIA Intravenous Cohort 2

Insufficient new directors

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Imugene Limited Announces That First Patient Dosed in VAXINIA Intratumoral Cohort 2

Imugene Limited, Annual General Meeting, Nov 17, 2022

Imugene Limited Announces First patient IV dosed in VAXINIA Phase 1 clinical trial

Imugene Limited Announces That Australian Government's Office of the Gene Technology Regulator (Ogtr) Has Granted Imugene the Dir Licence Required to Expand Its Vaxinia Phase 1 Clinical Trial Within Australia

Imugene Limited Doses First Patient in nextHERIZON Phase 2 Trial

Imugene Appoints Jakob Dupont as Non- Executive Director

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Imugene Limited Announces First Cohort 3 Patient Dosed in Clinical Trial of CHECKvacc

Imugene Limited Appoints Mike Tonroe as Chief Financial Officer, Effective from September 2022

Imugene Limited Announces Appointment of Dr. Sharon Yavrom as Executive Director, Clinical Scientist

Imugene Limited Announces Final HER-Vaxx Phase 2 Trial Overall Survival Results

Imugene Limited Announces Board Changes

City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors

Imugene Limited Receives Ethics Approval to Start Phase 2 nextHERIZON Clinical Trial of Cancer Immunotherapy HER-VAXX

Imugene Limited Announces First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc

Imugene Limited Announces Appointment of Steven Cha as Chief Medical Officer and Member of the Executive Management Team

Imugene Limited Receives Notice of Grant from the European Patent Office for Patent Application Number

Imugene Completes Phase 1a Monotherapy Dose Escalation of Immunotherapy PD1-Vaxx

Executive Chairman recently sold AU$37m worth of stock

Imugene Limited Receives US Food and Drug Administration (FDA) Investigational New Drug (IND) Approval to Initiate A Phase I Clinical Trial of its Oncolytic Virotherapy Candidate, Vaxinia (CF33-hNIS, HOV2)

Imugene Limited Provides Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc

Insider recently sold AU$1.4m worth of stock

Imugene Limited Provides Phase 1 Clinical Trial Update of Its Immunotherapy Pd1-Vaxx

Imugene Presents HER-Vaxx Update at ESMO World GI Congress

Imugene Limited Announces FDA IND Approval of New Oncolytic Virotherapy Checkvacc Virotherapy Checkvacc

Independent Non-Executive Director recently sold AU$1.2m worth of stock

Imugene Limited has completed a Follow-on Equity Offering in the amount of AUD 0.324115 million.

Revenue in line with expectations

Imugene Limited Commences Cohort 2 Dosing in Phase 1 PD1-Vaxx Trial

Imugene Limited Dose Escalates in Phase I Clinical Trial of New Checkpoint Immunotherapy PD1-VAXX

Imugene Limited Completes Recruitment to HER-Vaxx Phase 2 Trialim

Imugene Limited Completes Enrolment of First Cohort in Phase I Clinical Trial of New Checkpoint Immunotherapy PD1-Vaxx

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media